Home › Melanoma
Pag-aaral pangklinika para sa Melanoma na nagre-recruit sa U.S.
196 pag-aaral para sa Melanoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX59 pag-aaral
- New York City, NY38 pag-aaral
- Los Angeles, CA34 pag-aaral
- Nashville, TN32 pag-aaral
- Pittsburgh, PA31 pag-aaral
- Boston, MA25 pag-aaral
- Philadelphia, PA23 pag-aaral
- San Francisco, CA22 pag-aaral
- Salt Lake City, UT21 pag-aaral
- Columbus, OH21 pag-aaral
- Atlanta, GA21 pag-aaral
- Durham, NC20 pag-aaral
- Arlington, VA20 pag-aaral
- St. Louis, MO20 pag-aaral
- Dallas, TX20 pag-aaral
- Tampa, FL19 pag-aaral
- Denver, CO19 pag-aaral
- Aurora, CO18 pag-aaral
- San Diego, CA18 pag-aaral
- Washington, DC17 pag-aaral
- Cincinnati, OH17 pag-aaral
- Seattle, WA17 pag-aaral
- Grand Rapids, MI17 pag-aaral
- Jacksonville, FL16 pag-aaral
- Edison, NJ16 pag-aaral
- Rochester, MN16 pag-aaral
- Queens, NY16 pag-aaral
- Portland, OR15 pag-aaral
- Madison, WI15 pag-aaral
- San Antonio, TX15 pag-aaral
- Chicago, IL15 pag-aaral
- Orlando, FL15 pag-aaral
- Orange, CA14 pag-aaral
- Cleveland, OH13 pag-aaral
- Omaha, NE12 pag-aaral
- Ann Arbor, MI12 pag-aaral
- Minneapolis, MN12 pag-aaral
- Detroit, MI11 pag-aaral
- New Haven, CT11 pag-aaral
- Richmond, VA11 pag-aaral
Ayos sa estado
- Alabama12 pag-aaral
- Alaska5 pag-aaral
- Arizona26 pag-aaral
- Arkansas13 pag-aaral
- California70 pag-aaral
- Colorado32 pag-aaral
- Connecticut14 pag-aaral
- Delaware6 pag-aaral
- District of Columbia7 pag-aaral
- Florida55 pag-aaral
- Georgia23 pag-aaral
- Hawaii3 pag-aaral
- Idaho8 pag-aaral
- Illinois22 pag-aaral
- Indiana14 pag-aaral
- Iowa12 pag-aaral
- Kansas15 pag-aaral
- Kentucky21 pag-aaral
- Louisiana9 pag-aaral
- Maine4 pag-aaral
- Maryland24 pag-aaral
- Massachusetts28 pag-aaral
- Michigan31 pag-aaral
- Minnesota29 pag-aaral
- Mississippi3 pag-aaral
- Missouri22 pag-aaral
- Montana8 pag-aaral
- Nebraska16 pag-aaral
- Nevada6 pag-aaral
- New Hampshire6 pag-aaral
- New Jersey24 pag-aaral
- New Mexico11 pag-aaral
- New York50 pag-aaral
- North Carolina30 pag-aaral
- North Dakota9 pag-aaral
- Ohio40 pag-aaral
- Oklahoma14 pag-aaral
- Oregon15 pag-aaral
- Pennsylvania47 pag-aaral
- Rhode Island5 pag-aaral
- South Carolina10 pag-aaral
- South Dakota6 pag-aaral
- Tennessee39 pag-aaral
- Texas77 pag-aaral
- Utah26 pag-aaral
- Vermont5 pag-aaral
- Virginia34 pag-aaral
- Washington25 pag-aaral
- West Virginia7 pag-aaral
- Wisconsin20 pag-aaral
- Wyoming3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study of BI 3810944 in Patients With Advanced Cancer
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07224425Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07281924Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
4 Weeks – 99 Years · Lahat ng kasarian · Na-update Set 28, 2026 · NCT00040352A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06961006Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07519655A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06246916A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06172478BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05136196DESTINY-PANTUMOUR04
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07124000Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06548789A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
Nagre-recruitPhase 2
Hanggang edad 25 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07621614Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Nagre-recruitPhase 3
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT05727904Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
Nagre-recruitPhase 3
Edad 75 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07068074Pan-tumor MRD Study
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06605404Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06047379Intratumoral N17350 in Advanced Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07339176Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07661966Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Nagre-recruitPhase 1/2
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06814496A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06066138A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.
Nagre-recruit
Edad 18 hanggang 90 · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07830225Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT06529822R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Nagre-recruitPhase 1
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06398418Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05267626BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT04752826Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT04038619Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.